2. Academic Validation
  3. Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402

Lead optimization of N-3-substituted 7-morpholinotriazolopyrimidines as dual phosphoinositide 3-kinase/mammalian target of rapamycin inhibitors: discovery of PKI-402

  • J Med Chem. 2010 Jan 28;53(2):798-810. doi: 10.1021/jm9014982.
Christoph M Dehnhardt 1,  Aranapakam M Venkatesan,  Efren Delos Santos,  Zecheng Chen,  Osvaldo Santos,  Semiramis Ayral-Kaloustian,  Natasja Brooijmans,  Robert Mallon,  Irwin Hollander,  Larry Feldberg,  Judy Lucas,  Inder Chaudhary,  Ker Yu,  Jay Gibbons,  Robert Abraham,  Tarek S Mansour
Affiliations

Affiliation

  • 1 Discovery Medicinal Chemistry, Wyeth Research, Pearl River, New York 10965, USA. dehnhac@wyeth.com
PMID: 19968288 DOI: 10.1021/jm9014982
Abstract

Herein we describe the identification and lead optimization of triazolopyrimidines as a novel class of potent dual PI3K/mTOR inhibitors, resulting in the discovery of 3 (PKI-402). Compound 3 exhibits good physical properties and PK parameters, low nanomolar potency against PI3Kalpha and mTOR, and excellent inhibition of cell proliferation in several human Cancer cell lines. Furthermore, in vitro and in vivo biomarker studies demonstrated the ability of 3 to shut down the PI3K/Akt pathway and induce Apoptosis in Cancer cells. In addition, 3 showed excellent in vivo efficacy in various human Cancer xenografts, validating suppression of PI3K/mTOR signaling as a potential Anticancer therapy.

Figures